Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, filed this Form 6-K for the month of May 2023. The filing, dated May 5, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a standalone financial statement.
Material Changes
The filing text does not provide details on material changes versus prior periods. The content is limited to the notification of the press release issuance.
Guidance, Outlook, and Risks
Specific guidance, management commentary, risks, contingencies, or unusual items are not detailed within the body of this Form 6-K. These details are contained within the attached press release (Exhibit 99.1), which is incorporated by reference but not reproduced in the provided text.
Key Facts for Investor Verification
- Verify the content of the press release dated May 5, 2023 (Exhibit 99.1) for the specific announcement driving this filing.
- Confirm the company's status as a Form 20-F filer.
- Note that no financial data is presented directly in this filing text.